Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00044265 · ClinicalTrials.gov registry record · Phase 4
Treatment of Pediatric Hypertension With Altace Trial
A Phase 4 study, sponsored by Pfizer.
- Completed
- Registry status
- Phase 4
- Development phase
- 310
- Enrollment target
NCT00044265 is a Phase 4 study that has completed, run by Pfizer. The registered enrollment target is 310 participants.
The verdict
NCT00044265, a Phase 4 study, has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 310 participants
- Enrollment target
Study Summary
Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, however ramipril has not been extensively tested in children, and information regarding the efficacy and safety would therefore be of benefit to children. This study is designed to demonstrate the efficacy and safety of ramipril in the treatment of hypertension in children ages 6 through 16 years.
Interventions
- DRUG ramipril
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 310 participants |
| Start Date | 2002-07 |
| Est. Completion | 2004-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00044265
The ClinicalTrials.gov registry entry for NCT00044265 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 310 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ramipril is the first listed.
NCT00044265 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00044265 about?
NCT00044265 is a clinical study titled "Treatment of Pediatric Hypertension With Altace Trial". Ramipril is an ACE inhibitor that has been marketed in the US for the treatment of hypertension since 1991. It has been shown to be effective in reducing both systolic and diastolic blood pressure in adults when used once daily. ACE inhibitors are frequently used to treat hypertension in children, h...
What is the current status of trial NCT00044265?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 310 participants. The study started on 2002-07. Estimated completion is 2004-11.
What interventions are being tested in trial NCT00044265?
The interventions under investigation include: ramipril (DRUG).
Who is sponsoring clinical trial NCT00044265?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.